-
公开(公告)号：US11719710B2
公开(公告)日：2023-08-08
申请号：US16695713
申请日：2019-11-26
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Andrea Horsch , Dietmar Zdunek , Georg Hess
CPC classification number: G01N33/74 , C07K14/4716 , G01N33/6863 , G01N33/6893 , G01N2333/4712 , G01N2333/495 , G01N2333/52 , G01N2800/347 , G01N2800/50 , G01N2800/52
Abstract: The present disclosure relates to the field of laboratory diagnostics. Specifically, means and methods are disclosed for determining a patient's risk of suffering from acute kidney injury after a surgical procedure based on the detection of GDF-15, troponin T and/or a natriuretic peptide.
-
公开(公告)号：US20170082639A1
公开(公告)日：2017-03-23
申请号：US15358779
申请日：2016-11-22
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N33/6872 , G01N33/74 , G01N2333/47 , G01N2333/475 , G01N2800/347 , G01N2800/56
Abstract: Systems, kits, and methods for predicting the risk of an adverse event related to acute kidney injury AKI as a consequence of a surgical intervention in a subject. Embodiments of the system and methods include means and steps for determining an amount of liver-type fatty acid binding protein (L-FABP) in a sample, such as a urine-sample of a subject; comparing the amounts of the L-FABP with a reference amount, and predicting the risk of an adverse event related to acute kidney injury as a consequence of surgical intervention in the subject.
-
公开(公告)号：US09535073B2
公开(公告)日：2017-01-03
申请号：US13713719
申请日：2012-12-13
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Georg Hess , Andrea Horsch , Dietmar Zdunek
CPC classification number: G01N33/6893 , G01N33/6872 , G01N33/74 , G01N2333/47 , G01N2333/475 , G01N2800/347 , G01N2800/56
Abstract: Systems, kits, and methods for predicting the risk of an adverse event related to acute kidney injury AKI as a consequence of a surgical intervention in a subject. Embodiments of the system and methods include means and steps for determining an amount of liver-type fatty acid binding protein (L-FABP) in a sample, such as a urine-sample of a subject; comparing the amounts of the L-FABP with a reference amount, and predicting the risk of an adverse event related to acute kidney injury as a consequence of surgical intervention in the subject.
Abstract translation: 用于预测与受试者的外科手术相关的急性肾损伤AKI有关的不良事件风险的系统，试剂盒和方法。 该系统和方法的实施方案包括用于测定样品（例如受试者的尿液样品）中肝型脂肪酸结合蛋白（L-FABP）的量的方法和步骤; 将L-FABP的量与参考量进行比较，并且预测与受试者的外科手术相关的与急性肾损伤有关的不良事件的风险。
-
4.发明申请USE OF BIOMARKERS IN THE ASSESSMENT OF THE EARLY TRANSITION FROM ARTERIAL HYPERTENSION TO HEART FAILURE 审中-公开生物标记在评估从早期转移到心脏失效的早期转换中的使用公开(公告)号：US20140065648A1
公开(公告)日：2014-03-06
申请号：US13776314
申请日：2013-02-25
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Ursula-Henrike Wienhues-Thelen , Dirk Block , Hendrik Heudig , Sabine Vogel-Ziebolz , Christine Boehm , Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC: G01N33/68
CPC classification number: G01N33/54306 , G01N33/6887 , G01N33/6893 , G01N2333/4712 , G01N2333/495 , G01N2333/58 , G01N2800/325 , G01N2800/50 , G01N2800/52
Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.
Abstract translation: 用于诊断心脏衰竭前的心脏的功能和/或结构异常以及用于预测心脏衰竭发展的风险的方法和系统，包括测量样品中的心肌肌钙蛋白并将测量值与参考值进行比较。 在一些实施方案中也测量了其它标志物，包括GDF15和IGFBP7。
-
公开(公告)号：US10942175B2
公开(公告)日：2021-03-09
申请号：US14549632
申请日：2014-11-21
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Ursula-Henrike Wienhues-Thelen , Dirk Block , Hendrik Huedig , Sabine Vogel-Ziebolz , Christine Boehm , Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC: G01N33/543 , G01N33/68
Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.
-
Patent Agency Ranking
公开(公告)号：US20150293122A1
公开(公告)日：2015-10-15
申请号：US14540165
申请日：2014-11-13
Inventor： Ursula-Henrike Wienhues-Thelen , Georg Hess , Hendrik Huedig , Herbert von der Eltz , Andrew Emili , Anthony Gramolini , Peter Liu , David MacLennan , Vincent Fong , Ruth Isserlin , Thomas Kislinger , Dirk Block
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N2333/47 , G01N2333/4727 , G01N2333/4737 , G01N2333/4745 , G01N2333/5412 , G01N2333/58 , G01N2800/325 , G01N2800/56
Abstract: The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
Abstract translation: 本发明涉及用于评估体外心脏衰竭的方法，包括以下步骤：在样品中测量标记物IGFBP-7的浓度，任选地在样品中测量一种或多种其他心力衰竭标志物的浓度， 并且通过比较在IGFBP-7中确定的浓度和为任选的一种或多种其它标记确定的浓度与在参考群体中确定的该标志物或这些标记的浓度进行比较来评估心力衰竭。 还公开了在评估心力衰竭中使用IGFBP-7作为标记蛋白，包括IGFBP-7的标记组合和用于测量IGFBP-7的试剂盒。
-
7.发明申请USE OF BIOMARKERS IN THE ASSESSMENT OF THE EARLY TRANSITION FROM ARTERIAL HYPERTENSION TO HEART FAILURE 审中-公开生物标记在评估从早期转移到心脏失效的早期转换中的应用公开(公告)号：US20150079615A1
公开(公告)日：2015-03-19
申请号：US14549632
申请日：2014-11-21
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Ursula-Henrike Wienhues-Thelen , Dirk Block , Hendrik Huedig , Sabine Vogel-Ziebolz , Christine Boehm , Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC: G01N33/543
CPC classification number: G01N33/54306 , G01N33/6887 , G01N33/6893 , G01N2333/4712 , G01N2333/495 , G01N2333/58 , G01N2800/325 , G01N2800/50 , G01N2800/52
Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.
Abstract translation: 用于诊断心脏衰竭前的心脏的功能和/或结构异常以及用于预测心脏衰竭发展的风险的方法和系统，包括测量样品中的心肌肌钙蛋白并将测量值与参考值进行比较。 在一些实施方案中也测量了其它标志物，包括GDF15和IGFBP7。
-
公开(公告)号：US20130122530A1
公开(公告)日：2013-05-16
申请号：US13713719
申请日：2012-12-13
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Georg Hess , Andrea Horsch , Dietmar Zdunek
CPC classification number: G01N33/6893 , G01N33/6872 , G01N33/74 , G01N2333/47 , G01N2333/475 , G01N2800/347 , G01N2800/56
Abstract: Systems, kits, and methods for predicting the risk of an adverse event related to acute kidney injury AKI as a consequence of a surgical intervention in a subject. Embodiments of the system and methods include means and steps for determining an amount of liver-type fatty acid binding protein (L-FABP) in a sample, such as a urine-sample of a subject; comparing the amounts of the L-FABP with a reference amount, and predicting the risk of an adverse event related to acute kidney injury as a consequence of surgical intervention in the subject.
Abstract translation: 用于预测与受试者的外科手术相关的急性肾损伤AKI有关的不良事件风险的系统，试剂盒和方法。 该系统和方法的实施方案包括用于测定样品（例如受试者的尿液样品）中肝型脂肪酸结合蛋白（L-FABP）的量的方法和步骤; 将L-FABP的量与参考量进行比较，并且预测与受试者的外科手术相关的与急性肾损伤有关的不良事件的风险。
-
公开(公告)号：US20200333360A1
公开(公告)日：2020-10-22
申请号：US16916809
申请日：2020-06-30
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Georg Hess , Andrea Horsch , Dietmar Zdunek
Abstract: The present invention relates to a method for diagnosing a transitory ischemic attack (TIA) in a subject who is suspected to have exhibited a transitory ischemic attack, but who did not exhibit a stroke. The method is based on the determination of the amount of NT-proANP in a sample from said subject. Moreover, the present invention is directed to a method for diagnosing an acute cerebral ischemic event in a subject based on the determination of the amounts of NT-proBNP and NT-proANP in a sample from a subject. The method further comprises the step of calculating a ratio of the amounts of NT-proBNP and NT-proANP. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.
-
公开(公告)号：US10732188B2
公开(公告)日：2020-08-04
申请号：US14291676
申请日：2014-05-30
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC: A61K38/00 , C12Q1/68 , G01N33/567 , G01N33/74 , G01N33/68
Abstract: The present invention relates to a method for diagnosing a transitory ischemic attack (TIA) in a subject who is suspected to have exhibited a transitory ischemic attack, but who did not exhibit a stroke. The method is based on the determination of the amount of NT-proANP in a sample from said subject. Moreover, the present invention is directed to a method for diagnosing an acute cerebral ischemic event in a subject based on the determination of the amounts of NT-proBNP and NT-proANP in a sample from a subject. The method further comprises the step of calculating a ratio of the amounts of NT-proBNP and NT-proANP. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.022 seconds)
